ipxl20130514_8k.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K

 

CURRENT REPORT     


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


 

Date of Report (Date of earliest event reported): May 14, 2013


 

Impax Laboratories, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

001-34263

65-0403311

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

30831 Huntwood Avenue, Hayward, CA

94544

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code:

(510) 240-6000

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

Impax Laboratories, Inc. (the “Company”) held its 2013 Annual Meeting of Stockholders on May 14, 2013. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

 

Proposal 1: Election of Directors

 

Each of the following seven nominees for director were elected to serve a term of one year and until his successor has been elected and qualified.

 


Nominee

Votes For

Withheld Authority

Broker Non-Votes

Leslie Z. Benet, Ph.D.

20,265,186

31,126,437

7,994,393

Robert L. Burr

22,720,931

28,650,692

7,994,393

Allen Chao, Ph.D.

27,241,331

24,150,292

7,994,393

Nigel Ten Fleming, Ph.D.

20,386,093

31,005,530

7,994,393

Larry Hsu, Ph.D.

26,327,694

25,063,929

7,994,393

Michael Markbreiter

26,520,649

24,870,974

7,994,393

Peter R. Terreri

26,692,165

24,699,458

7,994,393

 


Proposal 2: Approve Second Amendment and Restatement of the Company’s 2002 Equity Incentive Plan


The resolution to approve the Second Amendment and Restatement of the Company’s 2002 Equity Incentive Plan, to, among other items, increase the aggregate number of shares of the Company’s common stock that may be issued under such plan by 3.15 million shares, was approved.


Votes For

Votes Against

Abstentions

Broker Non-Votes

40,408,761

10,797,846

185,016

7,994,393

 


Proposal 3: Advisory Vote on Executive Compensation


The resolution to approve, on a non-binding advisory basis, the compensation of our named executive officers was approved.


Votes For

Votes Against

Abstentions

Broker Non-Votes

43,401,625

7,818,989

171,009

7,994,393

 


Proposal 4: Ratification of Appointment of Independent Registered Public Accounting Firm


KPMG LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013.


Votes For

Votes Against

Abstentions

Broker Non-Votes

57,906,809

1,306,461

172,746

_

 

 
 

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

Dated: May 15, 2013 IMPAX LABORATORIES, INC.  
       
  By: /s/ Bryan M. Reasons  
    Name: Bryan M. Reasons  
    Title:   Senior Vice President, Finance, and  
                Chief Financial Officer